Jan Steyaert

Full Professor VUB, Research Director VIB, Founder ConfoTherapeutics

  • Pleinlaan 2

    1050 Brussels


  • Source: Scopus
  • Calculated based on number of publications stored in Pure and citations from Scopus
1970 …2023

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Last years, the Steyaert lab pioneered the use of nanobodies for chaperone-assisted X-ray crystallography (www.steyaertlab.eu), aiming at the highest hanging fruits of structural biology including membrane proteins, amyloidogenic proteins, and now also (transient) multiprotein complexes. The elucidation of the first GPCR structures in the agonist-bound active state demonstrate the power of Nanobodies to stabilize G protein coupled receptor conformational states including transmembrane signalling complexes. Recent work focusses on exploiting the conformational complexity of therapeutic targets for Nanobody-enabled drug discovery.

Appart of his research activities, Jan Steyaert is also a  serial entrepreneur. He is a co-founder of Ablynx (now a Sanofi company) and Biotalys and more recently he founded ConfoTherapeutics, three succesful biotech spin-offs that valorize a unique class of single domain antibodies (Nanobodies) derived from camelids.  



External positions

Director, Flanders Institute for Biotechnology

15 Dec 2016 → …

Founder & Senior advisor, Confo Therapeutics

15 May 2015 → …

Francqui Research Professor, FRANCQUI Stichting

1 Jan 20151 Dec 2017


Dive into the research topics where Jan Steyaert is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or